Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Gyre Therapeutics Q3 EPS $0.03 Beats $(0.02) Estimate, Sales $30.600M Miss $32.930M Estimate

Author: Benzinga Newsdesk | November 07, 2025 06:07am
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.02) by 250 percent. This is a 200 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $30.600 million which missed the analyst consensus estimate of $32.930 million by 7.08 percent. This is a 20.06 percent increase over sales of $25.488 million the same period last year.

Posted In: GYRE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist